Vertex Pharmaceuticals 주식 (NASDAQ: VRTX)

에 대한 최신 뉴스 Vertex Pharmaceuticals (NASDAQ:VRTX) 주식

VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

McDonald's Launches Limited-Edition Holiday Cups Co-Branded With Doodles

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

VOXX

VRTX

월요일(10일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다. 맥도날드, 온 세미컨덕터, 복스 인터내셔널, 로크웰 및 버텍스

월요일 주목해야 할 주식: 맥도날드, 온 세미컨덕터, 복스 인터내셔널, 로크웰 및 버텍스

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Health Care

Technicals

General

버텍스 파마슈티컬스(NASDAQ:VRTX)는 주가가 악성 데스 크로스(Death Cross)를 형성하면서 하락세 기술 신호를 받고 있다.

버텍스의 주가는 데스 크로스를 형성한 약세 차트와 힘겨루기 중

arm-qualcomm-shutter

Large Cap

Movers

CTAS

CVNA

MNDY

MSTR

PAYC

QCOM

SMCI

이들 11개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 노보 노디스크 A/S(NYSE:NVO)의 주식이 20.52% 하락했다. 이는 회사가 REDEFINE 1의 3상 시험 주요 결과를 발표한 후 발생한 일이다.

노보 노디스크, 버텍스 및 Arm은 지난주 최악의 성과를 보인 11개 대형주 중 일부 (12월 16-20일)

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement -
- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 -
- Continue to progress multiple novel, research-stage immunoprotective approaches -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vrtx.com%2F&amp;esheet=54230222&amp;newsitemid=20250328622122&amp;lan=en-US&amp;anchor=Vertex+Pharmaceuticals+Incorporated&amp;index=1&amp;md5=8b0996d221294fdf9df4f4bb3c2785ac">Vertex Pharmaceuticals Incorporated</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) today announced several updates on the Company's type 1 diabetes (T1D) portfolio.

Vertex Announces Program Updates For Type 1 Diabetes Portfolio; VX-264 Phase 1/2 Enrollment And Dosing Complete In Parts A And B: VX-264 Was Generally Safe And Well Tolerated; Efficacy Data Are Not Supportive Of Further Clinical Advancement

On CNBC's <a href="https://www.cnbc.com/video/2025/03/26/final-trades-chewy-wabtec-crown-castle-and-jpmorgan-chase.html">&#8220;Halftime Report Final Trades</a>,&#8221; Jim Lebenthal of Cerity Partners said he is long-term bullish but a bit nervous for the short term on Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
RBC Capital analyst Brian Abrahams, on Feb. 20, maintained Vertex Pharmaceuticals with a Sector Perform rating and raised the price target from<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings"> $407 to $408</a>.
Shannon Saccocia of NB Private Wealth named iShares U.S. Financials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYF#NYSE">IYF</a>) as her final trade.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joshua Brown of Ritholtz Wealth Management picked Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), saying the stock is close to its 52-week high.
Supporting his view, MoffettNathanson analyst Michael Nathanson, on March 17, upgraded Netflix from Neutral to Buy and raised the price target from $850 to $1100.
Price Action:
<ul>
<li>Vertex Pharmaceuticals shares gained 0.5% to close at $502.55 on Thursday.</li>
<li>iShares U.S. Financials ETF fell 0.6% during Thursday's session.</li>
<li>Netflix shares gained 0.6% to close at $976.72 on Thursday.</li>
</ul>
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock"> Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a></li>
</ul>
Photo: Shutterstock

Media

iShares Dow Jones US Financial Sector Index Fund

NFLX

Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'

Analyst Ratings

CNBC Halftime Report Final Trades: Vertex Pharmaceuticals, Netflix, iShares U.S. Financial ETF

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 20 years by 13.98% on an annualized basis producing an average annual return of 22.16%. Currently, Vertex Pharmaceuticals has a market capitalization of $129.85 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $5,245.54 today based on a price of $505.67 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742570109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 5 years by 2.37% on an annualized basis producing an average annual return of 19.23%. Currently, Vertex Pharmaceuticals has a market capitalization of $130.20 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a price of $507.02 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741896013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today

Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Vertex Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $76,828, and 8 are calls, for a total amount of $594,591.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $380.0 and $600.0 for Vertex Pharmaceuticals, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $380.0 to $600.0 in the last 30 days. 
<h3>Vertex Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741893347_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$100.0</td>
<td>$91.0</td>
<td>$93.7</td>
<td>$480.00</td>
<td>$159.2K</td>
<td align="right">76</td>
<td align="right">17</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$175.7</td>
<td>$171.0</td>
<td>$171.0</td>
<td>$400.00</td>
<td>$136.8K</td>
<td align="right">66</td>
<td align="right">0</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$34.7</td>
<td>$34.0</td>
<td>$34.0</td>
<td>$500.00</td>
<td>$125.8K</td>
<td align="right">473</td>
<td align="right">6</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$68.3</td>
<td>$62.2</td>
<td>$64.0</td>
<td>$450.00</td>
<td>$64.0K</td>
<td align="right">206</td>
<td align="right">0</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$45.6</td>
<td>$42.0</td>
<td>$42.01</td>
<td>$510.00</td>
<td>$50.4K</td>
<td align="right">16</td>
<td align="right">12</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Current Position of Vertex Pharmaceuticals</h3>
<ul>
<li>Trading volume stands at 1,034,376, with VRTX's price up by 1.51%, positioned at $502.93.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 53 days.</li>
</ul>
<h3>What The Experts Say On Vertex Pharmaceuticals</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $416.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Sector Perform rating on Vertex Pharmaceuticals, which currently sits at a price target of $408. 
&#x2A; Showing optimism, an analyst from Canaccord Genuity upgrades its rating to Hold with a revised price target of $424. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

COWZ

IBKR

CNBC Halftime Report Final Trades: Netflix, Meta Platforms, Vertex Pharmaceuticals, Interactive Brokers Group, Pacer US Cash Cows 100 ETF

As of March 11, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">2Seventy Bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>)</h3>
<ul>
<li>On March 10, 2seventy bio agreed to be acquired by Bristol Myers Squibb for $5.00 per share in 88% premium transaction valued at $286 million. &#8220;A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living with multiple myeloma and maximizing value for all stakeholders,&#8221; said Chip Baird, chief executive officer, 2seventy bio. &#8220;The strategic rationale for this acquisition is clear and today&#8217;s announcement represents the culmination of the journey for 2seventy bio." The company's stock gained around 20% over the past month and has a <a href="https://www.benzinga.com/quote/TSVT">52-week high of $5.99</a>.</li>
<li>RSI Value: 82.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>TSVT Price Action: Shares of 2Seventy Bio gained 5.3% to close at $2.80 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)</h3>
<ul>
<li>On Feb. 14, the FDA approved Sanofi's Merilog as a biosimilar to Novo Nordisk A/S‘ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Novolog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes mellitus.. The company's stock gained around 10% over the past month and <a href="https://www.benzinga.com/quote/SNY">has a 52-week high</a> of $60.12.</li>
<li>RSI Value: 77.4</li>
<li>SNY Price Action: Shares of Sanofi gained 0.2% to close at $59.35 on Monday.</li>
</ul>
<h3 class="wp-block-heading">Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)</h3>
<ul>
<li>On Feb. 10, Vertex Pharmaceuticals posted better-than-expected quarterly sales. &#8220;2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch of our fifth CF medicine, ALYFTREK; the continuing global launch of CASGEVY; and multiple ongoing pivotal trials. We are excited to drive diversification of the revenue base, disease areas of focus, R&amp;D pipeline, and geographies to continue to deliver long-term value to both patients and shareholders,&#8221; said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. The company's stock gained around 10% over the past month and has a <a href="https://www.benzinga.com/quote/VRTX">52-week high </a>of $519.88.</li>
<li>RSI Value: 74</li>
<li>VRTX Price Action: Shares of Vertex Pharmaceuticals gained 2.4% to close at $500.01 on Monday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44218016/top-3-financial-stocks-that-may-fall-off-a-cliff-in-march">Top 3 Financial Stocks That May Fall Off A Cliff In March</a></li>
</ul>

Short Ideas

TSVT

Top 3 Health Care Stocks That May Keep You Up At Night In Q1

In January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) Journavx, a non-opioid oral pain signal <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">inhibitor for acute pain</a>.
This marked the first approval of a new class of pain medication in more than 20 years, offering an alternative to <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43404756/fda-approves-first-non-opioid-pain-pill-as-medical-marijuana-remains-a-proven-alternative-for-relief" rel="noreferrer noopener">traditional opioid treatments</a>.
According to the Formulary Update released in February, Journavx has been <a target="_blank" href="https://www.optum.com/content/dam/noindex-resources/consumers/pdfs/forms/PharmacyPassages_Direct%20and%20UMR_February_2025.pdf" rel="noreferrer noopener">placed</a> on Tier 3 of Optum Rx Premium and Select Formularies and is being further evaluated by the Optum Rx National Pharmacy &amp; Therapeutics Committee for clinical value and safety. Many Tier 3 drugs have lower-cost options in Tier 1 or 2.
Optum Rx, is the pharmacy benefit manager owned by UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038618/hhs-challenges-vertex-over-fertility-services-program-tied-to-casgevy-gene-therapy" rel="noreferrer noopener">HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is &#8216;Grasping at Straws&#8217;</a>
According to Bloomberg, the interim decision ensures the drug will be covered, but patients may pay more since it&#8217;s not in the lower-cost tiers, which usually include generics or preferred brand drugs. This applies to Optum Rx&#8217;s Premium and Select formularies for commercial plans.
&#8220;With the growing concern over opioid use disorder, new non-opioid alternatives such as Journavx provide additional options for treatment,&#8221; the document says.
Citing a BMO Capital Markets analyst, the Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-03-06/vertex-non-opioid-pain-drug-gets-some-unitedhealth-coverage?sref=TBDibEcD" rel="noreferrer noopener">report</a> notes that a less favorable formulary placement will likely make it harder for some patients to access the medication. The report also notes a challenge Vertex will face: convincing insurers to cover its drug, which costs much more than opioids. The wholesale price is $15.50 per 50 mg tablet taken twice daily.
Concurrently, the UK Medicines and Healthcare products Regulatory Agency (MHRA) <a href="https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-uk-mhra-approval-alyftrekr" target="_blank" rel="noreferrer noopener">approved</a> Vertex&#8217;s Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination therapy for cystic fibrosis patients ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene.
In February, Vertex Pharmaceuticals reported fourth-quarter earnings per share of $3.50, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $3.57</a>.
Sales reached $2.91 billion, up 16% year over year, beating the consensus of $2.78 billion. Annual sales <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43607732/vertex-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">reached $11.20 billion</a>.
Vertex expects 2025 sales of $11.75 billion-$12 billion versus a consensus of $11.84 billion.
Price Action: VRTX stock is up 0.32% at $487.26 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44194539/eli-lillys-single-monthly-maintenance-shot-of-eczema-drug-shows-completely-clear-skin-at-3-years-in-50-of-trial-patients" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients</a></li>
</ul>

Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies

A new compound that provides the pain-relieving <a href="https://www.benzinga.com/markets/cannabis/24/01/36578723/huge-study-reveals-cannabis-provides-similar-pain-relief-benefits-as-opioids-without-negative-co">properties of cannabis</a> without the mind-altering effects can serve as an effective alternative to opioids for pain relief, according to researchers who developed the compound that mimics a natural molecule found in the cannabis plant.
Researchers from Washington University School of Medicine in St. Louis and Stanford University found the compound harnesses the pain-relieving properties of cannabis without causing addiction in mice.
"There is an urgent need to develop non-addictive treatments for chronic pain, and that's been a major focus of my lab for the past 15 years," said lead author Susruta Majumdar, Ph.D of Washington University School of Medicine.
"The custom-designed compound we created attaches to pain-reducing receptors in the body but by design, it can't reach the brain. This means the compound avoids psychoactive side effects such as mood changes and isn't addictive because it doesn't act on the brain's reward center," Majumdar said.
The <a href="https://www.nature.com/articles/s41586-025-08618-7">findings</a>, published in the journal Nature on March 5, showed that in both mouse models, injections of the modified compound eliminated touch hypersensitivity.
Majumdar, a professor of anesthesiology, explained in a Washington University <a href="https://medicine.washu.edu/news/compound-harnesses-cannabis-pain-relieving-properties-without-side-effects/">press release</a> that opioids dull the sensation of pain in the brain and hijack the brain's reward system, triggering the release of dopamine and feelings of pleasure, which make opioids so addictive.
Government surveys show analgesics, or medications that control pain, are the most commonly prescribed type of drug in hospitals. And, <a href="https://www.cdc.gov/nchs/products/databriefs/db491.htm">according</a> to the Centers for Disease Control drug overdoses related to opioids, including <a href="https://www.benzinga.com/topic/fentanyl">fentanyl</a> are among the leading causes of accidental death in the U.S. In 2022, some 82,000 deaths in the U.S. were linked to opioids.
"For millennia, people have turned to marijuana as a treatment for pain. Clinical trials also have evaluated whether cannabis provides long-term pain relief," said co-corresponding study author Professor Robert Gereau of Washington University&#8217;s Medicine Pain Center.
&#8220;But inevitably the psychoactive side effects of cannabis have been problematic, preventing cannabis from being considered as a viable treatment option for pain. However, we were able to overcome that issue," Gereau added.
Approximately 125 million opioid prescriptions were dispensed&nbsp;to American patients in 2023 to treat moderate to severe pain, <a href="https://www.cdc.gov/overdose-prevention/about/prescription-opioids.html#:~:text=Approximately%20125%20million%20opioid%20prescriptions">according</a> to the CDC.
In January 2025, the U.S. Food and Drug Administration <a href="https://www.benzinga.com/general/health-care/25/01/43404756/fda-approves-first-non-opioid-pain-pill-as-medical-marijuana-remains-a-proven-alternative-for-relief">approved</a> the first new pain reliever to hit the market in more than 20 years. This medication, produced by Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), is a non-opioid and therefore non-addictive. 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44166646/fda-approves-ars-pharmaceuticals-lower-dose-neffy-nasal-spray-for-emergency-allergy-treatment">FDA Approves ARS Pharmaceuticals&#8217; Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment</a></li>
</ul>
Photo: Shutterstock

Cannabis

Cannabis For Pain Relief: Scientists Develop New Compound Without Mind-Altering Effects — Alternative To Opioids?

Live On CNBC, Rob Sechan Announces Sold Vertex Pharmaceuticals

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$48.00</td>
<td>$81.9K</td>
<td>541</td>
<td align="right">474</td>
</tr>
<tr>
<td>MDGL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$380.00</td>
<td>$74.5K</td>
<td>42</td>
<td align="right">88</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$295.00</td>
<td>$34.6K</td>
<td>148</td>
<td align="right">31</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$20.00</td>
<td>$26.3K</td>
<td>2.6K</td>
<td align="right">26</td>
</tr>
<tr>
<td>SRPT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$110.00</td>
<td>$25.4K</td>
<td>86</td>
<td align="right">25</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$300.00</td>
<td>$91.7K</td>
<td>3</td>
<td align="right">15</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$960.00</td>
<td>$120.4K</td>
<td>79</td>
<td align="right">10</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$480.00</td>
<td>$27.2K</td>
<td>1.1K</td>
<td align="right">9</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$280.00</td>
<td>$32.2K</td>
<td>2</td>
<td align="right">6</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$590.00</td>
<td>$26.2K</td>
<td>7</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with neutral sentiment. It expires in 50 day(s) on April 17, 2025. Parties traded 200 contract(s) at a $48.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $81.9K, with a price of $410.0 per contract. There were 541 open contracts at this strike prior to today, and today 474 contract(s) were bought and sold. 
• For MDGL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on April 17, 2025. This event was a transfer of 25 contract(s) at a $380.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $74.5K, with a price of $2970.0 per contract. There were 42 open contracts at this strike prior to today, and today 88 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be neutral, expiring in 2 day(s) on February 28, 2025. This event was a transfer of 25 contract(s) at a $295.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $34.6K, with a price of $1387.0 per contract. There were 148 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be neutral, expiring in 324 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $1315.0 per contract. There were 2612 open contracts at this strike prior to today, and today 26 contract(s) were bought and sold. 
• Regarding SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we observe a call option trade with neutral sentiment. It expires in 79 day(s) on May 16, 2025. Parties traded 25 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.4K, with a price of $1020.0 per contract. There were 86 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with neutral sentiment. It expires in 2 day(s) on February 28, 2025. Parties traded 5 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $91.7K, with a price of $18346.0 per contract. There were 3 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bearish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $960.00 strike. The total cost received by the writing party (or parties) was $120.4K, with a price of $12040.0 per contract. There were 79 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 324 day(s) on January 16, 2026. Parties traded 5 contract(s) at a $480.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $5455.0 per contract. There were 1141 open contracts at this strike prior to today, and today 9 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bearish sentiment. It expires in 387 day(s) on March 20, 2026. Parties traded 6 contract(s) at a $280.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $5383.0 per contract. There were 2 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bullish, expiring in 688 day(s) on January 15, 2027. This event was a transfer of 5 contract(s) at a $590.00 strike. The total cost received by the writing party (or parties) was $26.2K, with a price of $5258.0 per contract. There were 7 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MDGL

SRPT

TGTX

10 Health Care Stocks Whale Activity In Today's Session

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 3.51% since its last report. The company recently reported that it has 4.56 million shares sold short, which is 1.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740503726_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 5.44%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Is Vertex Pharmaceuticals Gaining or Losing Market Support?

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a market capitalization of $123.81 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 15 years ago, it would be worth $1,163.65 today based on a price of $482.16 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740427214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years

25 analysts have shared their evaluations of Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $479.6, a high estimate of $550.00, and a low estimate of $407.00. This current average represents a 1.63% decrease from the previous average price target of $487.56. 
<img src="https://www.benzinga.com/files/images/story/2025/1740085227_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Vertex Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$408.00</td>
<td>$407.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$424.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$520.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$407.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$450.00</td>
<td>$433.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$467.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$550.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$459.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$433.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$460.00</td>
<td>$460.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$533.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$460.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$460.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$430.00</td>
<td>$426.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$500.00</td>
<td>$503.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$418.00</td>
<td>$509.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$520.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$535.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$522.00</td>
<td>$545.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$494.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Vertex Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vertex Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Discovering Vertex Pharmaceuticals: A Closer Look</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Vertex Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 15.66%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 31.35%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.7%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 4.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.11, Vertex Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Vertex Pharmaceuticals's Future

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $407 to $408.

Price Target

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $408

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst C. Gregory Peters upgraded the rating for Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) from Outperform to Strong Buy and raised the price target from $70 to $80. Mercury General shares closed at $50.09 on Tuesday. <a href="https://www.benzinga.com/quote/MCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Reginald Smith upgraded Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Underweight to Neutral and boosted the price target from $57 to $79. Upstart shares closed at $67.34 on Tuesday. <a href="https://www.benzinga.com/quote/upst/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Joseph Moore upgraded the rating for NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) from Equal-Weight to Overweight and increased the price target from $231 to $257. NXP Semiconductors shares closed at $210.97 on Tuesday. <a href="https://www.benzinga.com/quote/nxpi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Quinn Bolton upgraded GLOBALFOUNDRIES Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) from Hold to Buy and announced a $50 price target. Maplebear shares closed at $40.10 on Tuesday. <a href="https://www.benzinga.com/quote/gfs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity analyst Whitney Ijem upgraded the rating for Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Sell to Hold and raised the price target from $408 to $424. Vertex Pharmaceuticals shares closed at $455.22 on Tuesday. <a href="https://www.benzinga.com/quote/vrtx/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NXPI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="405" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105-1024x405.png" alt="" class="wp-image-778775" style="width:473px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105-1024x405.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105-300x119.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105-768x303.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12090113/image-105.png 1182w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

Upgrades

NXPI

UPST

This NXP Semiconductors Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Canaccord Genuity analyst Whitney Ijem upgrades Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Sell to Hold and raises the price target from $408 to $424.

Canaccord Genuity Upgrades Vertex Pharmaceuticals to Hold, Raises Price Target to $424

Truist Securities analyst Joon Lee maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and raises the price target from $460 to $520.

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $520

Press Releases

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Economics

Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research

Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

AM Best Assigns Credit Ratings to Torreyana Insurance Company, Inc.

Vertex to Participate in Upcoming March Investor Conferences

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

ALNY

COEP

IMGN

REGN

RPRX

SMMT

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

RBC Capital

Canaccord Genuity

Truist Securities

Scotiabank

Cantor Fitzgerald

Vertex Pharm

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

월요일(10일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식은 다음과 같다.
<ul>
<li>맥도날드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 오늘 개장 전 실적을 발표할 예정이며 매출 64억 4천만 달러, 주당순이익 2.84달러가 예상된다. 주가는 시간외 거래에서 0.02% 하락한 294.25달러를 기록했다.</li>
<li>온 세미컨덕터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>): 오늘 개장 전 실적을 발표할 예정이며, 매출 17억 6천만 달러, 주당순이익 97센트가 예상된다. 주가는 시간외 거래에서 0.5% 하락한 51.00달러를 기록했다.</li>
<li>복스 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOXX#NASDAQ">VOXX</a>): 3분기에 주당 1.90의 손실을 기록했으며, 지난해에는 주당 8센트의 이익을 기록했다. 매출은 1억 3,526만 달러에서 1억 5,517만 달러로 감소했다. 주가는 시간외 거래에서 0.3% 하락한 7.38달러를 기록했다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>로크웰 오토메이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>): 오늘 개장 전 실적을 발표할 예정이며 주당순이익 1.59달러, 매출 18억 8천만 달러로 예상된다. 주가는 시간외 거래에서 0.4% 하락한 267.35달러를 기록했다.</li>
<li>버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): 오늘 장 마감 후 실적을 발표할 에정이며 주당순이익 4.03달러, 매출 27억 8천만 달러로 예상된다. 주식은 금요일에 2.5% 하락한 469.32달러로 마감했다.</li>
</ul>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)는 주가가 악성 <a href="https://kr.benzinga.com/?s=%EB%8D%B0%EC%8A%A4+%ED%81%AC%EB%A1%9C%EC%8A%A4" target="_blank" rel="noopener">데스 크로스</a>(Death Cross)를 형성하면서 하락세 기술 신호를 받고 있다.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-722205" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM.png" sizes="(max-width: 628px) 100vw, 628px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07110320/Screenshot-2025-01-07-at-7.25.52-PM-300x231.png 300w" alt="" width="628" height="483" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">차트는 Benzinga Pro를 사용하여 생성되었습니다.</a>
이는 50일 이동 평균선이 200일 이동 평균선 아래로 떨어질 때 발생하며, 보통 장기적인 하락세의 전조로 여겨진다. 버텍스의 경우, 기술적 문제는 더 넓은 하락세와 일치하며, 지난 6개월 동안 15% 하락했고, 지난 한 달 동안에는 거의 14% 하락했다.
또한 읽어보세요: <a href="https://www.benzinga.com/insights/news/25/01/42851189/if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-this-much-today">20년 전에 이 주식에 1,000달러를 투자했다면 오늘 이 정도를 가졌을 것입니다.</a>
<h2 class="wp-block-heading">낙천적 낭만이 통증 완화제 실패로 가려지다</h2>
버텍스는 매출의 90% 이상을 낙관적으로 나타내는 낭만적 약물 프랜차이즈에서 얻고 있지만, 투자자들의 회의론을 뚫고 나갈 수 없었다.
2024년에는 CASGEVY를 통해 최초의 유전자 편집 기반 겸혈병 치료제로 주목을 받았다. 인사이더 머니에 <a href="https://www.insidermonkey.com/blog/jim-cramers-take-on-vertex-pharmaceuticals-vrtx-bold-predictions-for-the-future-1417241/">따르면</a>, 그러나 12월에는 기대를 모았던 비중독성 통증 완화제가 임상 시험 목표를 달성하지 못하면서 주가가 11% 하락했다.
<h2 class="wp-block-heading">VRTX 주식 차트는 낙관적이지 않다</h2>
VRTX 주식은 여러 매도 신호를 나타내고 있다:
<ul>
<li>이동 평균: 월요일 종가인 VRTX 주식이 $402.49로 50일($456.92) 및 200일($457.35) 이동 평균선 아래에 있으며, 이는 데스 크로스를 강화한다.</li>
<li>이동평균 수렴 발산 지표(MACD): -17.17의 부정적인 수치는 강한 하락 모멘텀을 나타낸다.</li>
<li>상대 강도 지수(RSI): 32.59로 주식이 과매도 수준에 가까워지고 있지만, 아직 반전 구역에 도달하지는 않았다.</li>
</ul>
<h2 class="wp-block-heading">크레이머의 호출이 압박을 받다</h2>
지난 8월, 짐 크레이머는 버텍스를 바이오텍에서 유망한 기업으로 찬양하며, 낙관적으로 나타내는 낭만적 약물과 <a href="https://www.benzinga.com/24/08/40624639/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics" target="_blank" rel="noopener" data-google-interstitial="false">통증 관리</a> 분야에서의 혁신적인 작업을 강조했다.
그 이후로 주가는 거의 18% 하락했으며, 이는 바이오텍 부문에 자주 발생하는 변동성을 반영한다.
버텍스의 기술적 및 기본적 문제는 투자자들이 반등을 보기 위해 인내가 필요할 수 있음을 시사한다.
주가 움직임: 버텍스의 주식은 화요일 1.45% 상승한 $408.32에 마감되었다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42652152/vertex-pharmaceuticals-alyftrek-is-an-accretive-opportunity-on-top-and-bottom-lines-say-bullish-analyst">버텍스 파마슈티컬스: 알리프트렉은 상단 및 하단 라인에 대한 &#8216;부가적 기회&#8217;입니다. 낙관적인 분석가가 말합니다.</a></li>
</ul>
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 대형주들은 지난 주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)의 주식이 20.52% 하락했다. 이는 회사가 <a href="https://www.benzinga.com//node/42613036" target="_blank" rel="noreferrer noopener">REDEFINE 1의 3상 시험</a> 주요 결과를 발표한 후 발생한 일이다.
2. 버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)의 주식은 14.33% 하락했다. 이는 회사가 <a href="https://www.benzinga.com//node/42599745" target="_blank" rel="noreferrer noopener">스즈트리진(</a><a href="https://www.benzinga.com//node/42599745" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">Suzetrigine</a><a href="https://www.benzinga.com//node/42599745" target="_blank" rel="noreferrer noopener">)의 2상 연구 결과</a>를 발표한 후 발생한 일이다.
3. XPO(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>)의 주식이 13.47% 하락했다.
4. 슈퍼 마이크로 컴퓨터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)의 주식이 13.33% 하락했다. 이는 회사가 <a href="https://kr.benzinga.com/news/usa/stocks/%EC%A7%84%EC%9E%85-%EB%AA%87-%EB%8B%AC-%EB%A7%8C%EC%97%90-%EB%82%98%EC%8A%A4%EB%8B%A5-100%EC%97%90%EC%84%9C-%EC%A0%9C%EC%99%B8-%EC%9C%84%EA%B8%B0%EC%97%90-%EC%B2%98%ED%95%9C-%EC%8A%88%ED%8D%BC/" target="_blank" rel="noopener">나스닥 100 지수에서 제외될 예정</a>이라고 발표한 후 발생한 일이다.
5. 누 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>)의 주식이 13.07% 급락했다. 이는 새로운 정부 재정 지출 패키지와 지난주 중앙은행 금리 인상이 글로벌 투자자 신뢰를 약화시키고 국가의 적자에 대한 우려를 불러일으킬 수 있기 때문이다.
6. Arm 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)의 주식이 13.01% 하락했다. 이는 퀄컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)과의 <a href="https://www.benzinga.com//node/42538739" target="_blank" rel="noreferrer noopener">지속적인 법적 분쟁</a>으로 인한 약세 때문으로 보인다.
7. 마이크론 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)의 주식이 12.08% 하락했다. 이는 회사가 혼재된 실적 결과와 현재 분기에 대한 부진한 가이던스를 발표한 후 발생한 일이다. 여러 애널리스트들도 <a href="https://www.benzinga.com//node/42594359" target="_blank" rel="noreferrer noopener">가격 전망을 하향 조정</a>했다.
8. 페이컴 소프트웨어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>)의 주식이 11.63% 하락했다. 이는 연준의 금리 결정으로 소프트웨어 주식이 매도세를 경험한 결과이다.
9. 신타스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>)의 주식이 11.50% 하락했다. 이는 회사가 <a href="https://www.benzinga.com//node/42588404" target="_blank" rel="noreferrer noopener">2분기 재무 실적</a>을 발표한 후 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/ctas/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 하향 조정</a>한 결과이다.
10. 워너 브라더스 디스커버리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)의 주식이 <a href="https://www.benzinga.com//node/42603589" target="_blank" rel="noreferrer noopener">11.43% 하락</a>했다.
11. 먼데이닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)의 주식이 11.20% 하락했다. 이는 씨티그룹이 주가 전망을 <a href="https://www.benzinga.com/quote/mndy/analyst-ratings" target="_blank" rel="noreferrer noopener">338달러에서 302달러로 하향 조정</a>한 후 발생한 일이다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EB%B0%94-%EB%A6%AC-%EC%98%A4%ED%86%A0-%EB%B0%8F-%EB%8B%A4%EB%8D%B4-%EB%A0%88%EC%8A%A4%ED%86%A0%EB%9E%91%EC%9D%B4-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC/" target="_blank" rel="noopener">테바, 리 오토 및 다덴 레스토랑이 지난주 최고 성과를 보여준 10개 대형주 중 일부 (12월 16-20일)</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

전 대통령 도널드 트럼프는 이전에 백악관에서 4년 동안 재직한 경험이 있기 때문에, 그가 <a href="https://www.benzinga.com/topic/2024-election">2024년 대선</a>에서 승리하여 두 번째 임기를 수행할 경우 어떤 주식과 섹터가 혜택을 볼 수 있을지 투자자들이 파악하는 데 도움이 될 수 있다.
트럼프가 백악관에 처음 입성한 2017년에 가장 잘 수행된 주식들을 살펴보겠다.
2017년 최고의 주식들: 주식 시장은 2017년에 인상적인 상승세를 보였으며, 이는 대통령의 <a href="https://www.benzinga.com/markets/futures/18/01/11066769/the-stock-markets-rally-under-trump-among-the-best-ever-heres-how-his">첫 해에 가장 좋은 성과 중 하나</a>였다.
SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)가 추적하는 S&amp;P 500은 2017년에 21.7% 상승했는데, 이는 2016년 +12.0% 상승에 비해 인상적인 상승률이다. 역사적으로 대통령 선거 연도가 다른 연도에 비해 뛰어난 성과를 거두었기 때문이다.
트럼프가 2024년에 재선될 가능성이 있는 만큼, 2017년 S&amp;P 500에서 가장 성과가 좋았던 10개 주식을 살펴보겠다. 이는 이전에 <a href="https://www.marketwatch.com/story/biggest-sp-500-winners-and-losers-of-2017-tech-health-care-and-home-builders-lead-2017-12-29">마켓워치</a>에 의해 보도된 내용다.
<ol>
<li>NRG 에너지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>): +132%, 유틸리티</li>
<li>얼라인 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>): +131%, 헬스케어</li>
<li>버텍스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>): +103%, 헬스케어</li>
<li>윈 리조트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>): +95%, 소비재</li>
<li>보잉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>): +89%, 산업재</li>
<li>마이크론 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>): +88%, 기술</li>
<li>D.R. 호튼 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>): +87%, 소비재, 주택 건설업체</li>
<li>페이팔 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>): +87%, 기술</li>
<li>엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>): +81%, 기술</li>
<li>풀테 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>): 81%, 소비재, 주택 건설업체</li>
</ol>
2017년의 상위 10개 주식들은 트럼프가 대통령인 것과 관련이 없는 이유로 상승세를 보였을 가능성이 있지만, 몇 가지 공통된 주제가 있으며 전 대통령과의 잠재적인 연결고리도 있다.
결과적으로 헬스케어, 소비재 및 기술 주식들이 상위 성과를 보이는 섹터로 나타났다.
특히 마이크론과 엔비디아가 모두 상위 10위 안에 든 점은 주목할 만한 사항으로, 이는 트럼프 대통령 하에서 반도체 섹터에 긍정적인 영향을 미칠 수 있다.
또한 두 개의 주택 건설사가 2017년 가장 성과가 좋았던 주식 중 두 개로 선정된 것은 중요한 추세일 수 있다. 주택 건설업체는 현재 부통령인 카멀라 해리스가 승리할 경우 주목할만한 섹터로 여겨져 왔으며, 트럼프는 중산층을 위한 <a href="https://www.benzinga.com/general/politics/24/08/40424431/harris-warns-trump-tax-plan-will-devastate-americans-vows-to-go-after-bad-actors-behind-food-pri">주택 건설 확대</a> 공약을 내세우고 있다.
알고 계셨나요?
<ul>
<li>의회가 막대한 투자를 하고 있습니다. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent102824">2024년 선거를 앞두고 그들이 매입하고 매각한 것에 대한 팁을 쉽게 알아보세요.</a></li>
</ul>
중요한 이유 (Why It&#8217;s Important): 과거의 결과가 미래의 결과를 보장하지는 않지만, 때때로 시장 추세는 패턴과 신호를 보여줄 수 있다.
2017년의 상위 성과 주식을 기반으로 볼 때, 트럼프가 2024년 대선에서 승리할 경우 투자자들은 헬스케어, 유틸리티, 반도체 및 주택 건설업체에 대한 <a href="https://www.benzinga.com/markets/equities/24/10/41213583/what-a-trump-win-could-mean-for-financial-energy-stocks-lessons-from-2016">노출을 준비</a>할 수 있다.
2024년 대선까지 2주도 채 남지 않았기 때문에, 투자자들은 트럼프나 해리스의 승리를 기준으로 포트폴리오를 조정하고 있을 가능성이 높다. 예측되는 근소한 선거 결과를 감안할 때, 투자자들은 두 후보 중 어느 쪽이 당선되더라도 혜택을 받을 수 있는 섹터를 살펴보는 것이 좋다.
프리덤 캐피털 마켓(Freedom Capital Markets)의 수석 글로벌 전략가 제이 우즈(Jay Woods)는 <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40515453/exclusive-trump-or-harris-12-stocks-2-etfs-could-win-no-matter-whos-president-says-market-strate">2024년 대선에서 트럼프나 해리스 승리 여부와 관계없이 주목해야 할 섹터와 주식</a>을 벤징가와 공유한 바 있다.
우즈는 방산 주식과 사이버 보안 주식을 2024년 대선 전 주목해야 할 두 개의 주요 섹터로 명명했다.
&#8220;이 섹터를 면밀히 주시해야 한다고 생각한다&#8221;라고 방산 섹터에 대해 우즈가 말했다.
우즈는 방산 주식이 지정학적 우려와 세계에서 발생하는 여러 문제들로 인해 계속해서 혜택을 받을 수 있다고 언급했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/10/41534317/if-trump-wins-2024-election-in-landslide-bettors-could-make-5x-20x-their-bets-at-uk-sports">트럼프가 2024년 대선에서 압승할 경우, 베팅자들은 영국 스포츠북에서 베팅금의 5배, 20배를 받을 수 있다.</a></li>
</ul>
사진: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Politics

ALGN

NVDA

PYPL

WYNN

트럼프 대통령 시기인 2017년 S&P 500에서 가장 우수한 성과를 거둔 10개 주식: 역사가 반복될까?

캐시 우드의 아크 인베스트(Ark Invest)가 아마존닷컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>), 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)에 대해 중요한 거래를 했다.
아마존 거래: 아크 인베스트는 최근 회사의 성장 궤도에 대한 우려에도 불구하고 아마존 주식 76,505주를 매수했다. 이 거래는 아크의 주력 펀드인 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 실행되었다.
이 조치는 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41234873/amazon-stock-downgrade-by-wells-fargo-a-bearish-signal-on-growth-concerns">웰스 파고</a>가 아마존의 주식을 비중확대(Overweight)에서 중립(Equal-Weight)으로 하향 조정한 후 발생했다. 웰스 파고는 성장 둔화와 치열한 경쟁을 이유로 들었다. 이 거래의 가치는 종가 182.72달러를 기준으로 약 1,398만 달러이다.
아마존의 주식은 웰스 파고가 성장 둔화와 경쟁을 이유로 주식을 하향 조정한 후 월요일에 하락했다. 또한 연방 판사가 연방거래위원회(FTC)의 아마존에 대한 반독점 소송이 진행될 수 있도록 허용한 판결로 인해 매도세가 <a href="https://www.benzinga.com/news/24/10/41216248/amazon-stock-is-sliding-monday-whats-going-on">촉발</a>되었다.
로빈후드 거래: 아크 인베스트는 로빈후의 주식 1,421,431주를 세 개의 ETF인 ARKK, ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) 및 Ark Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>))를 통해 매도했다. 이 결정은 로빈후드가 첫 투자자 데이를 발표하고 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41236863/robinhood-eyes-major-growth-with-new-trading-features-while-coinbase-rides-crypto-s">새로운 거래 기능</a>을 도입한 최근 발표에도 불구하고 이루어졌다. 이 거래의 가치는 종가 25.61달러를 기준으로 약 3,640만 달러이다.
코인베이스 거래: 아크 인베스트는 ARKF ETF를 통해 코인베이스의 주식 12,994주를 매수했다. 이 조치는 코인베이스의 주식이 회사가 <a href="https://www.benzinga.com/news/24/10/41191796/why-coinbase-global-shares-are-trading-higher-today">새로운 유럽 규제 요건에 대응하여 서비스 제공을 조정</a>한다고 발표한 후 급등한 것과 일치한다. 이 거래의 가치는 종가 167.69달러를 기준으로 약 218만 달러이다.
다른 주요 거래:
1. 아크는 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)의 주식 2,365주를 ARKW ETF를 통해 매수했다. 메타 거래는 140만 달러로 평가되었다. 화요일에 메타 주식은 592.89달러로 1.4% 상승 마감했다.
2. 아크 인베스트는 비바 시스템즈(VEEV)와 버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) 주식을 ARKG ETF를 통해 매도했다. 대신 리커젼 파마슈티컬스(RXRX)와 10X 지노믹스(TXG) 주식을 매수했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41221351/elon-musks-theory-gains-ground-polymarket-odds-soar-for-nick-szabo-being-named-bitcoin-cre?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">일론 머스크의 이론이 힘을 얻고 있나? HBO 다큐멘터리에서 닉 사보가 비트코인 창작자 사토시 나카모토로 지명될 가능성이 급등</a></li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Equities

ETFs

AMZN

ARKF

ARKK

ARKW

COIN

HOOD

아크 인베스트 거래: 아마존 주식 $1,400만 매수, 로빈후드 $3,600만 매도, 코인베이스와 메타 매수

전설적인 수학자이자 전 국가안보국(NSA) 암호 해독자인 짐 사이먼스(Jim Simons)가 설립한 헤지펀드인 르네상스 테크놀로지스(Renaissance Technologies)는 최근 8월 9일 미국 증권거래위원회(SEC)에 제출한 13F의 최신 <a href="https://www.benzinga.com/news/24/05/38768433/jim-simons-groundbreaking-quantitative-hedge-fund-founder-who-provided-exceptional-returns-for-inves">주요 주식 보유 현황을 공시</a>했다.
무슨 일이 (What Happened): 이 공시 서류는 르네상스를 역사상 가장 성공적인 헤지 펀드 중 하나로 만든 정량적 전략을 반영하여 펀드 포트폴리오의 중요한 변화를 <a href="https://www.sec.gov/Archives/edgar/data/1037389/000103738924000073/xslForm13F_X02/renaissance13Fq22024_holding.xml" target="_blank" rel="noopener">보여</a>준다.
이 중 가장 주목할 만한 기업은 덴마크의 거대 제약회사인 노보 노디스크 A/S(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)는 시장 가치가 13억 달러로 르네상스 포트폴리오의 2.22%를 차지한다. 주식이 15.03% 감소했음에도 불구하고 노보 노디스크는 여전히 펀드의 최고 보유 주식이다. 노보 노디스크는 비만 치료제 오젬픽(Ozempic)이나 위고비(Wegovy)로 유명하다.
주목할 만한 변화에서 팔란티어 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)는 이 포트폴리오의 1.70%를 차지하며 2위를 차지했다. 그러나 르네상스는 팔란티어 포지션을 16.56% 감소시켜 이 데이터 분석 회사의 전망에 대한 잠재적인 재평가를 예고했다.
AI 및 그래픽 처리 분야의 선두주자인 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)는 르네상스의 보유 지분이 크게 증가했다. 이 펀드는 엔비디아의 지분을 27.52% 증가시켜 포트폴리오의 1.47%로 세 번째로 큰 위치를 차지했다.
기타 주요 보유 종목으로는 버텍스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)와 유나이티드 테라퓨틱스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>)이 있으며, 이는 의료 부문에 대한 르네상스의 관심을 강조한다.
메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)는 보유 주식이 33.39% 크게 감소하여 현재 포트폴리오의 0.89%를 차지한다. 에어비앤비(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>)는 또한 23.11%의 상당한 감소를 경험했으며 이는 시장 가치 5억 1,576만 달러로 르네상스 보유 지분의 0.87%를 차지했다.
놀랍게도 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)은 전체 보유 지분의 0.80%와 시장 가치 4억 7,221만 달러로 9위를 차지하며 이 포트폴리오에서 새로운 포지션으로 등장했다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)는 르네상스가 지분을 14.20% 늘려 상위 10위 안에 들었다. 테슬라는 현재 이 포트폴리오의 0.69%를 차지하며 가치는 4억 594만 달러이다.
이 뉴스가 중요한 이유 (Why It Matters): 이번 13F에서는 최근 사이먼스가 <a href="https://www.benzinga.com/news/large-cap/23/09/34771681/hedge-fund-titan-peter-brown-built-a-large-language-model-35-years-ago-read-what-it-wrote">별세한 이후</a>에 피터 브라운(Peter Brown) CEO가 이끄는 르네상스 테크놀로지스의 투자 전략을 엿볼 수 있다. 이 펀드는 사이먼스가 개척한 접근 방식인 복잡한 수학적 모델과 알고리즘 거래를 지속적으로 활용하여 기존 투자 방식보다 지속적으로 뛰어난 성과를 거두었다.
탁월한 성과로 유명한 르네상스의 메달리온 펀드(Medallion Fund)는 1988년부터 2021년까지 연간 62%(수수료 제외 37%)의 수익률을 달성했다. 이 실적은 수익률 측면에서 워런 버핏을 능가하는 <a href="https://www.benzinga.com/news/24/04/38431687/jim-simons-a-math-professor-became-one-of-the-most-successful-investors-of-all-time-now-he-shares-hi" target="_blank" rel="noopener" data-google-interstitial="false">역대 최고의 투자자 중 한 명</a>으로 사이먼스의 유산을 확고히 했다.
포브스(Forbes)에 따르면 사망 당시 사이먼스의 <a href="https://www.benzinga.com/news/24/05/38768433/jim-simons-groundbreaking-quantitative-hedge-fund-founder-who-provided-exceptional-returns-for-inves" target="_blank" rel="noopener" data-google-interstitial="false">순자산</a>은 314억 달러로 추산되었다. 그의 유산은 금융을 넘어 수학과 과학 교육에 대한 자선 활동에 크게 기여하고 있다. 특히 1964년에 사이먼스는 국방 분석 연구소(Institute for Defense Analyses)에서 극비 직위를 맡아 소련 코드와 암호를 해독하는 NSA를 지원했다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40435655/warren-buffetts-189b-cash-pile-not-a-sign-of-looming-market-crash-says-fund-manager-everybody-gets-e">워런 버핏의 $1,890억 현금 더미는 다가오는 시장 붕괴의 징후가 아니라고 펀드매니저가 주장: &#8216;모두가 흥분하지만&#8230; 그렇게 큰 숫자는 아니다&#8217;</a></li>
</ul>
Image Via Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움으로 제작되었으며 Benzinga 편집자가 검토하고 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Vertex Pharmaceuticals

뉴스

에 대한 최신 뉴스 Vertex Pharmaceuticals (NASDAQ:VRTX) 주식

월요일, 2월 10, 2025

수요일, 1월 08, 2025

일요일, 12월 22, 2024

월요일, 10월 28, 2024

수요일, 10월 09, 2024

화요일, 8월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌